Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer

M Stares, A Swan, K Cumming, TE Ding, J Leach… - Frontiers in …, 2021 - frontiersin.org
Introduction: Despite significant advances in systemic anticancer therapy (SACT) for non-
small cell lung cancer (NSCLC), many patients still fail to respond to treatment or develop …

Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1≥ 50% progressing on first-line pembrolizumab

M Stares, E Doyle, S Chapple, G Raynes, J MacDonald… - Lung Cancer, 2024 - Elsevier
Background Most patients with advanced non-small cell lung cancer (NSCLC) treated with
first-line pembrolizumab monotherapy will experience progressive disease (PD). Only a …

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre

M Stares, V Chauhan, J Moudgil‐Joshi… - Cancer …, 2023 - Wiley Online Library
A subset of patients with metastatic renal cell carcinoma (mRCC) follow an indolent disease
course and may benefit from initial active surveillance (AS). However, selecting patients …

Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary

S Harvey, M Stares, JA Scott, TJV Thottiyil… - Cancer …, 2024 - Wiley Online Library
Background Biomarkers of systemic inflammation have been shown to predict outcomes in
patients with cancer of unknown primary (CUP). We sought to validate these findings in …

Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis

M Stares, K Purshouse, G Knowles, R Haigh… - British Journal of …, 2021 - nature.com
Abstract Background In the United Kingdom, national guidance published in 2010
recommended the establishment of specialist teams to improve clinical pathways for patients …